Published in Ann Surg on June 01, 2008
The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas (2010) 2.84
Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol (2010) 2.13
Epigenetic control of sexual differentiation of the bed nucleus of the stria terminalis. Endocrinology (2009) 1.35
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
Tautomycetin and tautomycin suppress the growth of medullary thyroid cancer cells via inhibition of glycogen synthase kinase-3beta. Mol Cancer Ther (2009) 1.05
Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther (2013) 1.01
Valproic acid induces Notch1 signaling in small cell lung cancer cells. J Surg Res (2008) 0.99
Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol (2010) 0.97
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors. Mol Cancer Ther (2009) 0.97
Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma in vitro and in vivo. Cancer (2012) 0.94
Inhibition of growth in medullary thyroid cancer cells with histone deacetylase inhibitors and lithium chloride. J Surg Res (2008) 0.94
Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther (2014) 0.93
Expression of the active Notch1 decreases MTC tumor growth in vivo. J Surg Res (2011) 0.91
Hesperetin, a potential therapy for carcinoid cancer. Am J Surg (2011) 0.90
Combination therapy with histone deacetylase inhibitors and lithium chloride: a novel treatment for carcinoid tumors. Ann Surg Oncol (2008) 0.88
Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology (2012) 0.85
Multi-targeted approach in the treatment of thyroid cancer. Minerva Chir (2010) 0.85
Notch in the development of thyroid C-cells and the treatment of medullary thyroid cancer. Am J Transl Res (2010) 0.85
Anti-tumor effects of the Notch pathway in gastrointestinal stromal tumors. Carcinogenesis (2012) 0.85
Histone deacetylase activity selectively regulates notch-mediated smooth muscle differentiation in human vascular cells. J Am Heart Assoc (2012) 0.84
Sodium butyrate activates Notch1 signaling, reduces tumor markers, and induces cell cycle arrest and apoptosis in pheochromocytoma. Am J Transl Res (2009) 0.83
Hesperetin activates the Notch1 signaling cascade, causes apoptosis, and induces cellular differentiation in anaplastic thyroid cancer. Ann Surg Oncol (2014) 0.82
Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices. BMC Cell Biol (2012) 0.81
Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol (2009) 0.81
Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications. J Clin Med Res (2016) 0.75
Expression of non-secreted IL-4 is associated with HDAC inhibitor-induced cell death, histone acetylation and c-Jun regulation in human gamma/delta T-cells. Oncotarget (2016) 0.75
Innovative in vitro chemo-hormonal drug therapy for refractory thyroid carcinomas. J Korean Med Sci (2012) 0.75
Antineoplastic effects of histone deacetylase inhibitors in neuroendocrine cancer cells are mediated through transcriptional regulation of Notch1 by activator protein 1. Cancer Med (2017) 0.75
Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem (1999) 8.16
Histone deacetylases, transcriptional control, and cancer. J Cell Physiol (2000) 3.18
Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 2.79
HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics. Cell Res (2007) 2.60
Notch activation induces apoptosis in neural progenitor cells through a p53-dependent pathway. Dev Biol (2004) 2.59
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol Cancer Ther (2005) 1.51
Notch signaling induces rapid degradation of achaete-scute homolog 1. Mol Cell Biol (2002) 1.51
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Effective long-term palliation of symptomatic, incurable metastatic medullary thyroid cancer by operative resection. Ann Surg (1998) 1.23
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Effects of the histone deacetylase inhibitor valproic acid on Notch signalling in human neuroblastoma cells. Br J Cancer (2005) 1.19
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica (2006) 1.16
Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid (2005) 1.14
Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci (2007) 1.14
Differentiation of medullary thyroid cancer by C-Raf-1 silences expression of the neural transcription factor human achaete-scute homolog-1. Surgery (1996) 1.09
The history of valproate in clinical neuroscience. Psychopharmacol Bull (2003) 1.06
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo. Prostate (2007) 1.06
Palliation of advanced thyroid malignancies. Surg Oncol (2007) 1.05
Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt/protein kinase B. Mol Cancer (2006) 1.04
Valproic acid induces apoptosis, p16INK4A upregulation and sensitization to chemotherapy in human melanoma cells. Cancer Biol Ther (2007) 1.03
HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol (2007) 0.98
Initial lymph node dissection increases cure rates in patients with medullary thyroid cancer. Asian J Surg (2007) 0.96
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs (2006) 0.91
Valproic acid inhibits growth, induces apoptosis, and modulates apoptosis-regulatory and differentiation gene expression in human thyroid cancer cells. Surgery (2005) 0.89
[Experimental study on the mechanism of the apoptosis of leukemic cells induced by valproic acid]. Zhonghua Er Ke Za Zhi (2005) 0.79
Carcinoid tumors. Oncologist (2008) 2.86
Is there still a glass ceiling for women in academic surgery? Ann Surg (2011) 2.33
Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab (2007) 2.26
Using body mass index to predict optimal thyroid dosing after thyroidectomy. J Am Coll Surg (2013) 2.10
Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 2.05
Pheochromocytoma: current approaches and future directions. Oncologist (2008) 2.05
Incidence and localization of ectopic parathyroid adenomas in previously unexplored patients. World J Surg (2013) 1.96
Valproic acid activates notch-1 signaling and regulates the neuroendocrine phenotype in carcinoid cancer cells. Oncologist (2007) 1.96
Inactivation of glycogen synthase kinase-3beta, a downstream target of the raf-1 pathway, is associated with growth suppression in medullary thyroid cancer cells. Mol Cancer Ther (2007) 1.85
The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid (2011) 1.85
Current management of medullary thyroid cancer. Oncologist (2008) 1.80
Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 1.78
Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid (2013) 1.77
Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2003) 1.76
Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? J Surg Res (2007) 1.75
A rising ioPTH level immediately after parathyroid resection: are additional hyperfunctioning glands always present? An application of the Wisconsin Criteria. Ann Surg (2010) 1.71
Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas (2013) 1.65
Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann Surg (2011) 1.64
Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 1.59
Isolated adrenal mass in patients with a history of cancer: remember pheochromocytoma. Ann Surg Oncol (2007) 1.56
Remnant uptake as a postoperative oncologic quality indicator. Thyroid (2013) 1.56
The utility of frozen section evaluation for follicular thyroid lesions. Ann Surg Oncol (2004) 1.53
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells. Mol Cancer Ther (2005) 1.53
25-hydroxyvitamin D status does not affect intraoperative parathyroid hormone dynamics in patients with primary hyperparathyroidism. Ann Surg Oncol (2010) 1.50
Can thallium-pertechnetate subtraction scanning play a role in the preoperative imaging for minimally invasive parathyroidectomy? Clin Nucl Med (2004) 1.47
Radioguided parathyroidectomy in patients with familial hyperparathyroidism. Ann Surg Oncol (2006) 1.46
Thyroidectomy decreases snoring and sleep apnea symptoms. Thyroid (2012) 1.46
Carcinoid tumors. Surg Oncol Clin N Am (2006) 1.45
Surgeon training and use of radioactive iodine in stage I thyroid cancer patients. Ann Surg Oncol (2012) 1.43
Pancreatic endocrine tumors. J Surg Res (2004) 1.42
Tertiary hyperparathyroidism: is less than a subtotal resection ever appropriate? A study of long-term outcomes. Surgery (2009) 1.42
Clinical efficacy of fine-needle aspiration biopsy of thyroid nodules in males. J Surg Res (2009) 1.42
The necessity and reliability of intraoperative parathyroid hormone (PTH) testing in patients with mild hyperparathyroidism and PTH levels in the normal range. World J Surg (2011) 1.42
All thyroid ultrasound evaluations are not equal: sonographers specialized in thyroid cancer correctly label clinical N0 disease in well differentiated thyroid cancer. Ann Surg Oncol (2014) 1.41
How Well Does Renal Transplantation Cure Hyperparathyroidism? Ann Surg (2015) 1.40
Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 1.39
The role of human achaete-scute homolog-1 in medullary thyroid cancer cells. Surgery (2003) 1.37
Apoptosis-mediated medullary thyroid cancer growth suppression by the PI3K inhibitor LY294002. Surgery (2006) 1.34
Secondary and tertiary hyperparathyroidism, state of the art surgical management. Surg Clin North Am (2009) 1.34
Treatment of advanced carcinoid tumors. Curr Opin Oncol (2006) 1.32
Clinical practice guideline: improving voice outcomes after thyroid surgery. Otolaryngol Head Neck Surg (2013) 1.32
Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol (Oxf) (2008) 1.31
The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell (2013) 1.30
Long-term follow-up of patients with tertiary hyperparathyroidism treated by resection of a single or double adenoma. Ann Surg (2002) 1.30
Hairy Enhancer of Split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 1.28
Surgery for primary hyperparathyroidism: what is the best approach? Ann Surg (2002) 1.26
Notch 1 signaling is active in ovarian cancer. Gynecol Oncol (2010) 1.23
Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: the surgical approach of choice for patients with mediastinal parathyroid adenomas? J Bone Miner Res (2002) 1.22
Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg (2006) 1.22
Suberoyl bis-hydroxamic acid activates Notch-1 signaling and induces apoptosis in medullary thyroid carcinoma cells. Oncologist (2008) 1.21
What is the clinical significance of an elevated parathyroid hormone level after curative surgery for primary hyperparathyroidism? Ann Surg (2009) 1.20
Suberoyl bishydroxamic acid inhibits cellular proliferation by inducing cell cycle arrest in carcinoid cancer cells. J Gastrointest Surg (2007) 1.19
Gastrointestinal carcinoid tumors: factors that predict outcome. World J Surg (2004) 1.18
The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs (2006) 1.17
Accuracy of fine-needle aspiration biopsy for predicting neoplasm or carcinoma in thyroid nodules 4 cm or larger. Arch Surg (2009) 1.17
Is minimally invasive parathyroidectomy associated with greater recurrence compared to bilateral exploration? Analysis of more than 1,000 cases. Surgery (2012) 1.17
New developments in the diagnosis and treatment of thyroid cancer. CA Cancer J Clin (2013) 1.16
Identification and validation of Notch pathway activating compounds through a novel high-throughput screening method. Cancer (2010) 1.15
Medical student operative experience correlates with a match to a categorical surgical program. Am J Surg (2003) 1.15
Total thyroidectomy: a safe and effective treatment for Graves' disease. J Surg Res (2011) 1.15
Medullary thyroid cancer: the functions of raf-1 and human achaete-scute homologue-1. Thyroid (2005) 1.14
Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol (2012) 1.14
Contralateral papillary thyroid cancer: does size matter? Am J Surg (2009) 1.14
Postoperative parathyroid hormone testing decreases symptomatic hypocalcemia and associated emergency room visits after total thyroidectomy. Surgery (2010) 1.14
Radioguided parathyroidectomy in patients with secondary and tertiary hyperparathyroidism. Surgery (2003) 1.12
Why do students choose careers in surgery? J Surg Res (2004) 1.12
MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets. Endocr Relat Cancer (2010) 1.11
Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol (2012) 1.10
Parathyroid hormone deficiency after total thyroidectomy: incidence and time. J Surg Res (2010) 1.10
Calciphylaxis in the absence of end-stage renal disease. Endocr Pract (2006) 1.09
New trends in parathyroid surgery. Curr Probl Surg (2010) 1.09
Lithium ions: a novel treatment for pheochromocytomas and paragangliomas. Surgery (2007) 1.09
Histone deacetylase inhibitors upregulate Notch-1 and inhibit growth in pheochromocytoma cells. Surgery (2008) 1.08
The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res (2007) 1.08
In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid (2011) 1.08
Creation of a "Wisconsin index" nomogram to predict the likelihood of additional hyperfunctioning parathyroid glands during parathyroidectomy. Ann Surg (2013) 1.07
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. Curr Opin Investig Drugs (2008) 1.06
In-vivo activation of Raf-1 inhibits tumor growth and development in a xenograft model of human medullary thyroid cancer. Anticancer Drugs (2006) 1.06
Radioguided parathyroidectomy for recurrent hyperparathyroidism caused by forearm graft hyperplasia. J Bone Miner Res (2003) 1.06
Older age and larger tumor size predict malignancy in hürthle cell neoplasms of the thyroid. Ann Surg Oncol (2008) 1.06